On November 12, 2026 Commit Biologics ("Commit"), the biotechnology company pioneering complement-powered immune engagers, reported the nomination of its first development candidate, as well as making two senior appointments, as it transitions from platform discovery to clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

COM002 is the first candidate to emerge from Commit’s proprietary Bispecific Complement Engager (BiCE) platform, producing antibodies which harness the power of the complement system to safely target and eliminate specific cells. COM002 builds on Commit’s platform-validating data in non-human primates, announced in November 2025, which showed rapid, deep and sustained targeted B cell depletion with no treatment-related safety findings and without systemic cytokine release.

During 2026, Commit has built the translational data package required to support COM002’s progression to the clinic, initially targeting relapsed/refractory non-Hodgkin lymphoma, with plans to expand into several autoimmune indications.

Beyond COM002, Commit is advancing a growing pipeline of innovative therapies to unlock the broader potential of the BiCE platform across oncology and autoimmune diseases.

Mikkel Wandahl Pedersen, CSO of Commit Biologics, said: "COM002 is our first clinical development candidate of an entirely new class of immune engagers, with potential applications in cancer and autoimmune disease. The nomination is a critical milestone, as we seek to show how our BiCE platform could revolutionise treatment, just as previous classes of immunotherapies, like T cell engagers and checkpoint inhibitors, have done."

Thomas L. F. Montgomery Andresen, CEO of Commit Biologics, said: "Nominating the first complement-powered immune engager is a pivotal moment for Commit, as we look ahead to taking COM002 into the clinic and unlock the potential of our BiCE platform. It is also a great pleasure to welcome two new members of our leadership team, who both have tremendous strengths and the hands-on experience that we need."

Anne-Marie Levy Rasmussen, newly-appointed Chief Operating Officer, said: "Commit has an inspiring ambition to define a new category of medicine, and I look forward to ensuring we execute on our milestones to get BiCE antibodies to patients as fast as possible."

Benjamin Ole Wolthers, newly-appointed Head of Clinical Development, said: "Being part of Commit’s pioneering effort using the complement system in immunotherapy is a privilege. Developing COM002 will be a great opportunity to showcase the treatment possibilities of this new drug class."

Anne-Marie Levy Rasmussen brings 25 years of executive leadership in operations, commercial strategy and large-scale transformation. Most recently, she was Chief Operating Officer at Gubra. Before that, she was CEO of Innovation Fund Denmark, with a portfolio of around €1 billion, built Bavarian Nordic’s global commercial organisation, and spent 12 years in senior leadership roles at GSK. She holds an MSc in Physics from the Niels Bohr Institute, University of Copenhagen.

Benjamin Ole Wolthers is a physician scientist with strong international experience in drug development. His career started in frontline care of children with leukaemia at Rigshospitalet in Copenhagen, and he later undertook development leadership at Kite Pharma, Galapagos and most recently Evaxion. At Kite and Galapagos, he led global teams responsible for early-stage and registrational CAR-T trials, while he oversaw clinical development strategy for first-in-human trials at Evaxion. At Commit, he will lead clinical development, translational medicine and regulatory strategy, and will lead COM002 into Phase 1 trials.

(Press release, Commit Biologics, NOV 12, 2026, View Source [SID1234674727])